© 2000 American Heart Association, Inc.
UltraRapid Communication |
Phosphate Regulation of Vascular Smooth Muscle Cell Calcification
From the Departments of Bioengineering (S.J., C.M.G.) and Pathology (C.E.M., C.M.G.), University of Washington, Seattle, Wash; Dentistry (M.D.M) and Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada; and Second Department of Internal Medicine (A.S., Y.N., K.M., H.M.), Osaka City University Medical School, Osaka, Japan.
Abstract—Vascular calcification is a common finding in atherosclerosis and a serious problem in diabetic and uremic patients. Because of the correlation of hyperphosphatemia and vascular calcification, the ability of extracellular inorganic phosphate levels to regulate human aortic smooth muscle cell (HSMC) culture mineralization in vitro was examined. HSMCs cultured in media containing normal physiological levels of inorganic phosphate (1.4 mmol/L) did not mineralize. In contrast, HSMCs cultured in media containing phosphate levels comparable to those seen in hyperphosphatemic individuals (>1.4 mmol/L) showed dose-dependent increases in mineral deposition. Mechanistic studies revealed that elevated phosphate treatment of HSMCs also enhanced the expression of the osteoblastic differentiation markers osteocalcin and Cbfa-1. The effects of elevated phosphate on HSMCs were mediated by a sodium-dependent phosphate cotransporter (NPC), as indicated by the ability of the specific NPC inhibitor phosphonoformic acid, to dose dependently inhibit phosphate-induced calcium deposition as well as osteocalcin and Cbfa-1 gene expression. With the use of polymerase chain reaction and Northern blot analyses, the NPC in HSMCs was identified as Pit-1 (Glvr-1), a member of the novel type III NPCs. These data suggest that elevated phosphate may directly stimulate HSMCs to undergo phenotypic changes that predispose to calcification and offer a novel explanation of the phenomenon of vascular calcification under hyperphosphatemic conditions. The full text of this article is available at http://www.circresaha.org.
Key Words: vascular calcification • hyperphosphatemia • inorganic phosphate • human smooth muscle cell • sodium-dependent phosphate transport • Pit-1 • Cbfa-1
This article has been cited by other articles:
 |
|
 |
|
  S. Mathew, K. S. Tustison, T. Sugatani, L. R. Chaudhary, L. Rifas, and K. A. Hruska The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1092 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Orita, H. Yamamoto, N. Kohno, M. Sugihara, H. Honda, S. Kawamata, S. Mito, N. N. Soe, and M. Yoshizumi Role of Osteoprotegerin in Arterial Calcification: Development of New Animal Model Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2058 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mathew, R. J. Lund, F. Strebeck, K. S. Tustison, T. Geurs, and K. A. Hruska Reversal of the Adynamic Bone Disorder and Decreased Vascular Calcification in Chronic Kidney Disease by Sevelamer Carbonate Therapy J. Am. Soc. Nephrol., January 1, 2007; 18(1): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Qunibi Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S95 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Speer, Y.-C. Chien, M. Quan, H.-Y. Yang, H. Vali, M. D. McKee, and C. M. Giachelli Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro Cardiovasc Res, May 1, 2005; 66(2): 324 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Davies, Richard. J. Lund, S. Mathew, and K. A. Hruska Low Turnover Osteodystrophy and Vascular Calcification Are Amenable to Skeletal Anabolism in an Animal Model of Chronic Kidney Disease and the Metabolic Syndrome J. Am. Soc. Nephrol., April 1, 2005; 16(4): 917 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kurihara, Y. Tsuruta, and T. Akizawa Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial Nephrol. Dial. Transplant., February 1, 2005; 20(2): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bottger and L. Pedersen Two Highly Conserved Glutamate Residues Critical for Type III Sodium-dependent Phosphate Transport Revealed by Uncoupling Transport Function from Retroviral Receptor Function J. Biol. Chem., November 1, 2002; 277(45): 42741 - 42747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Speer, M. D. McKee, R. E. Guldberg, L. Liaw, H.-Y. Yang, E. Tung, G. Karsenty, and C. M. Giachelli Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein-deficient Mice: Evidence for Osteopontin as an Inducible Inhibitor of Vascular Calcification In Vivo J. Exp. Med., October 21, 2002; 196(8): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cozzolino, A. S. Dusso, H. Liapis, J. Finch, Y. Lu, S. K. Burke, and E. Slatopolsky The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2299 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke and S. G. Rostand Progression of vascular calcification in uraemic patients: can it be stopped? Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1365 - 1368. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. DOHERTY, H. UZUI, L. A. FITZPATRICK, P. V. TRIPATHI, C. R. DUNSTAN, K. ASOTRA, and T. B. RAJAVASHISTH Rationale for the role of osteoclast-like cells in arterial calcification FASEB J, April 1, 2002; 16(6): 577 - 582. [Abstract] [Full Text] [PDF]
|
|